Crossmark

Long-term outcome of combination therapy with corticosteroids, mizoribine and RAS inhibitors as initial therapy for severe childhood IgA vasculitis with nephritis

Crossref DOI link: https://doi.org/10.1007/s00467-023-06052-3

Published Online: 2023-06-29

Published Print: 2023-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nagai, Sadayuki

Horinouchi, Tomoko https://orcid.org/0000-0003-1655-6030
Ninchoji, Takeshi

Ichikawa, Yuta

Tanaka, Yu

Kitakado, Hideaki

Ueda, Chika

Kondo, Atsushi

Aoto, Yuya

Sakakibara, Nana

Kaito, Hiroshi

Tanaka, Ryojiro

Shima, Yuko

Fujimura, Junya

Kamiyoshi, Naohiro

Ishimori, Shingo

Nakanishi, Koichi

Yoshikawa, Norishige

Iijima, Kazumoto

Nozu, Kandai
License Information

Text and Data Mining valid from 2023-06-29

Version of Record valid from 2023-06-29
More Information

Article History

Received: 16 March 2023

Revised: 23 May 2023

Accepted: 24 May 2023

First Online: 29 June 2023

Declarations

:

: This study involving human participants was conducted in accordance with the Declaration of Helsinki. Ethics approval was obtained from the Kobe University Graduate School of Medicine Ethics Review Committee (IRB number: B190137).

: Informed consent for kidney biopsy was obtained from all patients, but the need for informed consent to publish details of the cases was waived due to the retrospective nature of this study.

: The authors declare no conflicts of interest.

Document is current

Any future updates will be listed below